CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-25 | Sukhatme Mayukh President & CIO | Sale | −500,000 | $34.13 | $17.1M | 18,677,617 |
| 2026-06-25 | Sukhatme Mayukh President & CIO | Option exercise · Stock Option (Right to Buy) | −500,000 | 14,724,363 | ||
| 2026-06-24 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,813,063 |
| 2026-06-24 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −153,766 | $33.05 | $5.1M | 1,659,297 |
| 2026-06-24 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −46,234 | $33.51 | $1.5M | 1,613,063 |
| 2026-06-24 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 4,244,834 | ||
| 2026-06-20 | Pulik Richard CFO | Shares withheld for taxes | −2,129 | $31.43 | $67K | 276,420 |
| 2026-06-20 | Humes Jennifer Chief Accounting Officer | Shares withheld for taxes | −3,582 | $31.43 | $113K | 109,782 |
| 2026-05-22 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,813,063 |
| 2026-05-22 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $30.27 | $6.1M | 1,613,063 |
| 2026-05-22 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 4,444,834 | ||
| 2026-05-20 | Venker Eric President & Immunovant CEO | Shares withheld for taxes 10b5-1 | −34,483 | $32.41 | $1.1M | 1,613,063 |
| 2026-05-20 | Pulik Richard CFO | Shares withheld for taxes | −18,962 | $32.41 | $615K | 278,549 |
| 2026-04-20 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,847,546 |
| 2026-04-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $29.59 | $5.9M | 1,647,546 |
| 2026-04-20 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 4,644,834 | ||
| 2026-04-20 | Pulik Richard CFO | Grant or award | +60,644 | 297,511 | ||
| 2026-04-20 | Pulik Richard CFO | Grant or award · Stock Option (Right to Buy) | +84,026 | 84,026 | ||
| 2026-04-20 | Humes Jennifer Chief Accounting Officer | Grant or award | +29,173 | 113,364 | ||
| 2026-04-20 | Humes Jennifer Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +27,157 | 27,157 |
Page 8 of 29 · 570 trades